Metacrine Obtains $36,000,000 Series A Funding

  • Feed Type
  • Date
    8/5/2015
  • Company Name
    Metacrine
  • Mailing Address
    12780 El Camino Real San Diego, CA 92130 USA
  • Company Description
    Metacrine is a biotech company ?founded in 2015 on technology licensed from the ?laboratory of Dr. Ronald Evans, a world leader in? nuclear hormone receptors and Howard Hughes?Medical Institute Investigator at the Salk Institute. Metacrine will leverage two mechanistically distinct programs to target diabetes, steatohepatitis and other metabolic and liver disorders.
  • Website
    http://www.metacrine.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $36,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    elop two classes of novel therapeutics, to target diabetes, non-alcoholic steatohepatitis (NASH) and other metabolic diseases and liver disorders.
  • M&A Terms
  • Venture Investor
    ARCH Venture Partners
  • Venture Investor
    EcoR1 Capital Management
  • Venture Investor
    Polaris Partners
  • Venture Investor
    venBio

Trending on Xconomy